To evaluate the efficacy of EGFR-TKIs in EGFR-positive lung cancer patients, we included 160 LUAD, 52 ASC, and 65 LUSC patients who were treated with any EGFR-TKI monotherapy or combination therapies in the clinic (Supplementary Table 2). Here, EGFR is linked to lung carcinoma.